Overview

Treatment of Primary CNS Lymphoma ( FTD )

Status:
Completed
Trial end date:
2019-03-02
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the efficacy and safety of FTD regiment (fotemustine, temozolomide and dexamethasone ) for patients with primary CNS lymphoma.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mingzhi Zhang
Collaborator:
Zhengzhou University
Treatments:
Cytarabine
Dexamethasone
Fotemustine
Temozolomide
Criteria
Inclusion Criteria:

Age range 14-69 years old;KPS performance statusā‰„60 or ECOG performance status 0-2;
Estimated survival time > 3 months; Histological confirmed PCNSL; None of chemotherapy
contraindication;At least one measurable lesion according to RECIST;None of other serious
diseases;Patients could be followed up;None of other relative treatments including the
traditional Chinese medicine, immunotherapy,biotherapy except anti-bone metastasis therapy
and other symptomatic treatments.

volunteers who signed informed consent.

Exclusion Criteria:

Currently undergoing chemotherapy, radiotherapy and targeted therapy (received chemotherapy
within 3 weeks, received radiotherapy within 2 weeks, or has not recovered from any
previous treatment of acute toxicity);Patients with uncontrolled medical problems
(including active infection, uncontrolled diabetes, severe heart, liver, kidney dysfunction
and interstitial pneumonia, etc.); Pregnant or lactating women;Serious medical illness
likely to interfere with participation;Chemotherapy contraindication such as cachexia;
patients with other malignancies previously;Serious infection;The evidence of peripheral
nervous disorder or dysphrenia; patients estimated to be unsuitable by investigato